EUVIMEDEUVIMED entdecken
Crossref

Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway

Lei Hua, Nianhui Yang, Yue Li, Kexiu Huang iD, Xinya Jiang, Fangshu Liu, Zhi Yu, Jie Chen, Jing Lai, Juan Du, Hui Zeng iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Lei Hua und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Metformin, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax inhibits acute myeloid leukaemia by inhibiting BCL‐2 targeting, and a combination regimen with venetoclax has been explored. Although these regimens produce better clinical results, the vast majority of patients still suffer from disease recurrence or primary drug resistance. Metformin has been demonstrated to induce apoptosis in cancer cells. However, whether it can synergize with venetoclax and the underlying mechanisms of metformin‐induced apoptosis are not fully understood. In this study, we investigated the effect of metformin and venetoclax on the growth of AML cells in vitro and in vivo . In both Molm13 and THP‐1 cell lines, metformin and venetoclax synergistically inhibited the proliferation and induced apoptosis of leukaemia cells. Most importantly, the combination of metformin and venetoclax treatment significantly increased the expression levels of the endoplasmic reticulum (ER) stress‐related marker CHOP, for example, in AML cell lines. Knockdown of CHOP markedly attenuated the metformin‐ and venetoclax‐induced cell apoptosis. Moreover, the combination of metformin and venetoclax demonstrated prominent anti‐leukaemia effects in xenograft models and bone marrow samples from AML patients. In summary, the combination of metformin and venetoclax showed enhanced anti‐leukaemia activity with acceptable safety in AML patients, representing a new combinatorial strategy worth further clinical investigation to treat AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminLeukemia, Myeloid, AcuteHumansCell Line, TumorNeoplasm Recurrence, LocalProto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicApoptosisEndoplasmic Reticulum StressSulfonamides

Stichwörter der Autor:innen

CHOPacute myeloid leukaemiaapoptosisendoplasmic reticulum stressmetformin

Substanzen

MetforminProto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamides

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.

ORCID-Profile: Kexiu Huang, Hui Zeng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hua, L., Yang, N., Li, Y., Huang, K., Jiang, X., Liu, F., Yu, Z., Chen, J., Lai, J., Du, J., & Zeng, H. (2023). Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway. British Journal of Haematology. https://doi.org/10.1111/bjh.18968

Vancouver

Hua L, Yang N, Li Y, Huang K, Jiang X, Liu F, et al. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway. British Journal of Haematology. 2023. doi:10.1111/bjh.18968

BibTeX
@article{Hua2023,
  author = {Hua, Lei and Yang, Nianhui and Li, Yue and Huang, Kexiu and Jiang, Xinya and Liu, Fangshu and Yu, Zhi and Chen, Jie and Lai, Jing and Du, Juan and Zeng, Hui},
  title = {Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress— CHOP pathway},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18968}
}
Kostenlos starten →